Johnson & Johnson Other Operating Income or Expenses 2012-2026 | JNJ
Johnson & Johnson annual/quarterly other operating income or expenses history and growth rate from 2012 to 2026. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
- Johnson & Johnson other operating income or expenses for the quarter ending March 31, 2026 were $-0.294B, a 104.02% decline year-over-year.
- Johnson & Johnson other operating income or expenses for the twelve months ending March 31, 2026 were $-0.406B, a 108.07% decline year-over-year.
- Johnson & Johnson annual other operating income or expenses for 2025 were $7.209B, a 253.58% decline from 2024.
- Johnson & Johnson annual other operating income or expenses for 2024 were $-4.694B, a 29.24% decline from 2023.
- Johnson & Johnson annual other operating income or expenses for 2023 were $-6.634B, a 719.01% increase from 2022.
|
Johnson & Johnson Annual Other Operating Income or Expenses (Millions of US $) |
|
|---|---|
| 2025 | $7,209 |
| 2024 | $-4,694 |
| 2023 | $-6,634 |
| 2022 | $-810 |
| 2021 | $-526 |
| 2020 | $-2,899 |
| 2019 | $-2,525 |
| 2018 | $-1,405 |
| 2017 | $42 |
| 2016 | $-210 |
| 2015 | $2,064 |
| 2014 | $70 |
| 2013 | $-2,498 |
| 2012 | $-1,626 |
| 2011 | $-2,743 |
|
Johnson & Johnson Quarterly Other Operating Income or Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-294 |
| 2025-12-31 | $-483 |
| 2025-09-30 | $478 |
| 2025-06-30 | $-107 |
| 2025-03-31 | $7,321 |
| 2024-12-31 | $161 |
| 2024-09-30 | $-1,798 |
| 2024-06-30 | $-653 |
| 2024-03-31 | $-2,404 |
| 2023-12-31 | $421 |
| 2023-09-30 | $-499 |
| 2023-06-30 | $384 |
| 2023-03-31 | $-6,940 |
| 2022-12-31 | $-413 |
| 2022-09-30 | $-226 |
| 2022-06-30 | $-273 |
| 2022-03-31 | $102 |
| 2021-12-31 | $-46 |
| 2021-09-30 | $-1,850 |
| 2021-06-30 | $488 |
| 2021-03-31 | $882 |
| 2020-12-31 | $-2,354 |
| 2020-09-30 | $-1,200 |
| 2020-06-30 | $-24 |
| 2020-03-31 | $679 |
| 2019-12-31 | $-16 |
| 2019-09-30 | $-4,214 |
| 2019-06-30 | $1,683 |
| 2019-03-31 | $22 |
| 2018-12-31 | $-978 |
| 2018-09-30 | $-3 |
| 2018-06-30 | $-364 |
| 2018-03-31 | $-60 |
| 2017-12-31 | $53 |
| 2017-09-30 | $297 |
| 2017-06-30 | $-527 |
| 2017-03-31 | $219 |
| 2016-12-31 | $254 |
| 2016-09-30 | $54 |
| 2016-06-30 | $-557 |
| 2016-03-31 | $39 |
| 2015-12-31 | $1,205 |
| 2015-09-30 | $-420 |
| 2015-06-30 | $931 |
| 2015-03-31 | $348 |
| 2014-12-31 | $-963 |
| 2014-09-30 | $1,345 |
| 2014-06-30 | $-226 |
| 2014-03-31 | $-86 |
| 2013-12-31 | $-868 |
| 2013-09-30 | $-943 |
| 2013-06-30 | $-172 |
| 2013-03-31 | $-515 |
| 2012-12-31 | $-319 |
| 2012-09-30 | $90 |
| 2012-06-30 | $-2,008 |
| 2012-03-31 | $611 |
| 2011-12-31 | $-2,858 |
| 2011-09-30 | $308 |
| 2011-06-30 | $-206 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |